HEPA

Hepion Pharma earns a Neutral rating, with a 41.1 composite and low conviction at 2/5. Regulatory is the strongest pillar at 49, supported by an enforcement subscore of 80 and a jurisdiction score of 50, although the 25 cadence subscore limits the contribution. Fundamentals score 41, reflecting mixed operating data and minimal scale. Market contributes 40 despite no available quote from institutional pricing feeds, constraining price-based confirmation. Editorial ranks weakest at 30, with no newsroom or brief activity in CIN newsroom coverage. The resulting profile supports neither a clear rerating case nor an Underweight stance.

Licensed fundamentals data show flat year-over-year revenue and a breakeven operating margin, creating no evidence of commercial growth but avoiding an operating-margin penalty. Net income was approximately $34.9 million, while EBITDA remained negative at roughly $3.7 million, indicating that bottom-line profitability did not translate into positive core earnings. Market capitalization was approximately $1.75 million, producing a zero market-cap tier subscore, while the cash-burn ratio stood near 2.14 and cash runway scored 15. Primary regulatory filings show no reported events across either the 90-day or 180-day periods and no enforcement hits. However, no latest filing date was available, leaving filing cadence as the principal regulatory weakness.

The clearest forward catalyst sits within the regulatory pillar because that category already leads the framework and carries the strongest internal driver through its 80 enforcement score. A current primary regulatory filing could improve the weak cadence component, establish a dated disclosure baseline, and provide concrete information on the cannabinoid pipeline without relying on unavailable market pricing or absent editorial momentum. Such a filing would also help clarify whether flat revenue, breakeven operating margin, negative EBITDA, and positive net income represent a durable operating configuration or a period-specific outcome. The single most important signal to watch is the appearance of a current primary regulatory filing that materially improves filing cadence.